Oxcarbazepine (Epilepsy)

Neural Tube Defects

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S7659
R22653		 Tomson (Oxcarbazepine) , 2018 Neural tube defects at least 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 2.52 [0.10;61.96] C 0/333   1/2,514 1 333
ref
S6071
R15799		 Morrow (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2006 Neural tube defect 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 33.10 [1.23;890.88] C 0/7   1/647 1 7
ref
Total 2 studies 8.87 [0.71;110.59] 2 340
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Tomson (Oxcarbazepine) , 2018Tomson, 2018 1 2.52[0.10; 61.96]133351%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Morrow (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2006Morrow, 2006 2 33.10[1.23; 890.88]1749%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 17% 8.87[0.71; 110.59]23400.9100.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Oxcarbazepine; 2: Oxcarbazepine) (Controls exposed to Lamotrigine, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 8.87[0.71; 110.59]234017%NATomson (Oxcarbazepine) , 2018 Morrow (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2006 2 case control studiescase control studies 0 Type of controls exposed to other treatment, sickexposed to other treatment, sick 8.87[0.71; 110.59]234017%NATomson (Oxcarbazepine) , 2018 Morrow (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2006 2 Tags Adjustment   - No  - No 8.87[0.71; 110.59]234017%NATomson (Oxcarbazepine) , 2018 Morrow (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2006 2 All studiesAll studies 8.87[0.71; 110.59]234017%NATomson (Oxcarbazepine) , 2018 Morrow (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2006 20.5100.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls exposed to other treatment, sick controlsexposed to other treatment, sick controls 8.87[0.71; 110.59]234017%NATomson (Oxcarbazepine) , 2018 Morrow (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2006 20.510.01.0